PARProceedings of Anticancer Research2208-35452208-3553Bio-Byword Scientific Publishing Pty. Ltd.10.26689/par.v8i6.8873ArticleStudy on the Diagnostic Value of Serum Tumor Markers CEA, CA153, and CYFRA21 in Invasive Breast Cancerhttps://artdesignp.com/journal/PAR/8/6/10.26689/par.v8i6.8873XuDonghong,LiJinmei,LiQian2024862024-11-22Objective: To explore the diagnostic value of serum tumor markers CEA, AFP, CA199, CA125, CA153, CYFRA21, CA724, and NSE in invasive breast cancer. Methods: A total of 314 patients with invasive breast cancer from Baoding First Central Hospital between January 2021 and December 2022, and 31 patients with benign breast diseases (including mastitis, breast fibroadenoma, breast adenosis, adenoma of the breast, benign phyllodes tumor of the breast, and intraductal papilloma) were randomly selected as the control group. The levels of CEA, AFP, CA199, CA125, CA153, CYFRA21, CA724, and NSE were measured using electrochemiluminescence. Results: The serum concentrations of CEA, CA153, and CYFRA21 showed significant statistical differences between the invasive breast cancer group and the benign breast disease group (P < 0.01). ROC curve analysis revealed that CA153 had the highest sensitivity for diagnosing invasive breast cancer, while CEA had the highest specificity, at 84.4% and 77.4%, respectively. When multiple tumor markers were used for the diagnosis of invasive breast cancer, the combination of CEA and CA153 showed the highest specificity at 90.3%, while the combination of CEA and CYFRA21 had the highest sensitivity at 88.2%. The combined detection of CEA, CYFRA21, and CA153 had the largest area under the curve (AUC) on the ROC curve, at 0.802, indicating that the combination of these three markers provided the best diagnostic performance for invasive breast cancer. Conclusion: CEA, CA153, and CYFRA21 can be used for the diagnosis of invasive breast cancer, and the combined detection of these three markers offers the best diagnostic efficacy for invasive breast cancer.

Sung H, Ferlay J, Siegel RL, et al., 2021, Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin, 71(3): 209–249. https://doi.org/10.3322/caac.21660

Li T, Mello-Thoms C, Brennan PC, 2016, Descriptive Epidemiology of Breast Cancer in China: Incidence, Mortality, Survival and Prevalence. Breast Cancer Res Treat, 159(3): 395–406. https://doi.org/10.1007/s10549-016-3947-0

Jacobs AT, Martinez Castaneda-Cruz D, Rose MM, et al., 2022, Targeted Therapy for Breast Cancer: An Overview of Drug Classes and Outcomes. Biochem Pharmacol, 204: 115209. https://doi.org/10.1016/j.bcp.2022.115209

Pang C, Ma Y, Shi W, et al., 2024, Prognostic Significance of Serum Tumor Markers in Various Pathologic Subtypes of Gastric Cancer. J Gastrointest Surg, 28(5): 694–702. https://doi.org/10.1016/j.gassur.2024.02.023

Stokkel LE, van Rossum HH, van de Kamp MW, et al., 2023, Clinical Value of Preoperative Serum Tumor Markers CEA, CA19-9, CA125, and CA15-3 in Surgically Treated Urachal Cancer. Urol Oncol, 41(7): 326.e17–326.e24. https://doi.org/10.1016/j.urolonc.2023.01.018

Hiramatsu K, Takahashi K, Yamaguchi T, et al., 2005, N1, N12-Diacetylspermine as A Sensitive and Specific Novel Marker for Early- and Late-Stage Colorectal and Breast Cancers. Clin Cancer Res, 11(8): 2986–2990. https://doi.org/10.1158/1078-0432.CCR-04-2275

Yi L, Liu X, Lin D, et al., 2012, The Value of Combined Detection of Serum CA153, CA125, and CEA in the Diagnosis of Breast Cancer. Journal of Chongqing Medical University, 37: 802–805.

Luo D, Chi Y, Wang X, 2018, Clinical Significance of Combined Detection of CA153, CA125, and CEA in the Diagnosis of Breast Cancer. Chinese Medical Innovations, 15: 134–137.

Qiu S, Zeng Y, Ye Y, 2021, Analysis of the Diagnostic Value of Combined Detection of CA153 and CEA in Breast Cancer. China Practical Medicine, 16: 78–80.

Wang H, Cai D, Luan Y, et al., 2019, Evaluation of the Diagnostic Value of CEA, CA125, CA153, and CYFRA211 in Triple-Negative Breast Cancer. Journal of Tropical Medicine, 9: 1082–1085.

Hing JX, Mok CW, Tan PT, et al., 2020, Clinical Utility of Tumour Marker Velocity of Cancer Antigen 15-3 (CA 15-3) and Carcinoembryonic Antigen (CEA) in Breast Cancer Surveillance. Breast, 52: 95–101. https://doi.org/10.1016/j.breast.2020.05.005

Zhang J, Wei Q, Dong D, et al., 2021, The Role of TPS, CA125, CA15-3 and CEA in Prediction of Distant Metastasis of Breast Cancer. Clin Chim Acta, 523: 19–25. https://doi.org/10.1016/j.cca.2021.08.027

Uygur MM, Gümüş M, 2021, The Utility of Serum Tumor Markers CEA and CA 15-3 for Breast Cancer Prognosis and Their Association with Clinicopathological Parameters. Cancer Treat Res Commun, 28: 100402. https://doi.org/10.1016/j.ctarc.2021.100402

Rong S, Hu Y, Liu J, et al., 2022, The Value of Detecting Carbohydrate Antigen 153, Carbohydrate Antigen 125, and Human Epidermal Growth Factor Receptor-2 Levels in the Diagnosis of Breast Cancer. Journal of Cancer Research and Therapeutics, 35: 140–142.

Wan J, 2018, The Value of Combined Detection of Serum Tumor Markers CA153, CA125, CEA, and HER-2 in the Diagnosis of Breast Cancer. Modern Medical Journal, 33: 119–121.

Fu J, 2023, Diagnostic Value of Combined Serum CEA, CA125, CA153, and HER2 in Breast Cancer. Chinese Medical Innovations, 20: 105–108.

Wei X, Du W, Zhai S, et al., 2022, Diagnostic Value of Combined Detection of Serum Carcinoembryonic Antigen, Carbohydrate Antigen 125, and Carbohydrate Antigen 153 in Breast Cancer. Oncology Progress, 20: 2465–2472.

Liu K, Chen Y, 2021, Application Value of Combined Detection of Serum CEA, CA153, and HE4 in the Diagnosis of Breast Cancer. Modern Diagnosis and Treatment, 32: 1761–1762.

Liu C, Li S, Zhang J, 2023, Diagnostic Value of Combined Detection of Serum CA153 and miR-335 in Early Breast Cancer. Laboratory Medicine and Clinic, 20: 1046–1049.

Wang W, Xu X, Tian B, et al., 2017, The Diagnostic Value of Serum Tumor Markers CEA, CA19-9, CA125, CA15-3, and TPS in Metastatic Breast Cancer. Clin Chim Acta, 470: 51–55. https://doi.org/10.1016/j.cca.2017.04.023